Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.

Haiyun WangDouglas YeeDavid PotterPatricia JewettChristina YauHeather BeckwithAllison WatsonNicholas O'GradyAmy WilsonSusie BrainPaula Pohlmannnull nullAnne H Blaes

Published in: Breast cancer research and treatment (2024)

We found no difference in pCR rates by BMI with actual body weight-based neoadjuvant chemotherapy in this biologically high-risk breast cancer population in the I-SPY2 trial.

Keyphrases

neoadjuvant chemotherapy
body weight
body mass index
locally advanced
lymph node
phase iii
study protocol
sentinel lymph node
phase ii
clinical trial
weight gain
rectal cancer
physical activity
randomized controlled trial
squamous cell carcinoma
radiation therapy